Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 23;12(9):138.
doi: 10.1038/s41408-022-00733-2.

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

Sarvarinder K Gill  1 , Rashmi Unawane  2 , Shuqi Wang  3 , Jaeil Ahn  3 , Adolfo Aleman  2 , David S Siegel  2 , David H Vesole  2 , Harsh Parmar  2 , Pooja Phull  2 , Noa Biran  2
Affiliations

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

Sarvarinder K Gill et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Kaplan Meier curve.
Overall OS (A), OS for quad/penta exposed versus quad/penta refractory (B), and PFS for quad/penta exposed versus quad penta refractory (C) OS = Overall survival; PFS = progression free survival.
See this image and copyright information in PMC

References

    1. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33:3911–20. doi: 10.1200/JCO.2014.59.1503. - DOI - PMC - PubMed
    1. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–62. doi: 10.1182/blood-2016-01-631200. - DOI - PMC - PubMed
    1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20. doi: 10.1182/blood-2007-10-116129. - DOI - PMC - PubMed
    1. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125:3076–84. doi: 10.1182/blood-2014-09-568915. - DOI - PubMed
    1. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–19. doi: 10.1056/NEJMoa1506348. - DOI - PubMed

MeSH terms